- €9.49bn
- €9.62bn
- €1.89bn
Brief: Orion Portfolio Transfer Expected To Have EUR 31 Mln Positive Impact 2023 Results
Brief: Orion And Glykos Announce Research Collaboration
Brief: Orion, MSD Initiate Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
Brief: Navamedic Says Co And Orion Corporation Sign Non-Binding Term Sheet For Flexilev In Europe
Brief: Orion Animal Health Gets FDA Approval For Bonqat®
Brief: FDA Says It Approves Pregabalin Oral Solution For Alleviating Anxiety Associated With Transportation And Veterinary Visits In Cats
Jefferies ups Orion to 'hold' on post 2025 growth potential
Brief: Orion Expects 2023 Operating Profit To Be Slightly Higher Than In 2022
Brief: Orion Q3 Operating Profit EUR 80 Million Vs. Estimate EUR 66 Million
Earnings Poll: Orion Oyj third quarter results due on October 26
Brief: Orion Announces European Commission Approval For Ztalmy
Drug maker Orion slides on Q2 miss, outlook cut
Brief: Orion H1 Operating Profit Falls To EUR 102.0 Million
Earnings Poll: Orion second quarter results due on July 17
Brief: Orion Invests EUR 30 Mln To Increase Production Capacity In Finland
Europe Research Roundup: Carlsberg, Orion, Swedbank
Brief: Orion Keeps 2023 Outlook
Brief: Orion Q1 Operating Profit in Line with Consensus
Earnings Poll: Orion Oyj first quarter results due on April 27